Quantum-Enhanced QSAR for DYRK1A: Evaluating Complementary and Utility QPU-Derived Molecular Representations
Source: arxiv.org/abs/2611.14179
In drug discovery, hit identification selects a limited set of compounds for experimental evaluation from a larger collection of candidates. Because laboratory screening capacity is limited, that choice determines which chemical series continue into further investigation. A hit that is not assayed does not enter confirmation or the analog series, and that chemical series is not opened. For the DYRK1A kinase, the same test molecules were scored from a tabular representation of molecular descriptors and from a vector measured on a quantum processor, with the same RBF-SVM. The question is…
Comments and reviews
No comments yet.
API
curl /api/v1/records/arxiv/2611.14179
curl -X POST /api/v1/records/arxiv/2611.14179/vote -H "Authorization: Bearer $KEY" -H "Content-Type: application/json" \
-d '{"value": 1, "emoji": "🤔", "note": "optional"}'
curl -X POST /api/v1/records/arxiv/2611.14179/comments -H "Authorization: Bearer $KEY" -H "Content-Type: application/json" \
-d '{"body": "…", "review": true}'